[go: up one dir, main page]

HRP20000755A2 - Method of increasing bone toughness and stiffness and reducing fractures - Google Patents

Method of increasing bone toughness and stiffness and reducing fractures Download PDF

Info

Publication number
HRP20000755A2
HRP20000755A2 HR20000755A HRP20000755A HRP20000755A2 HR P20000755 A2 HRP20000755 A2 HR P20000755A2 HR 20000755 A HR20000755 A HR 20000755A HR P20000755 A HRP20000755 A HR P20000755A HR P20000755 A2 HRP20000755 A2 HR P20000755A2
Authority
HR
Croatia
Prior art keywords
bone
pth
months
vertebral
increase
Prior art date
Application number
HR20000755A
Other languages
English (en)
Croatian (hr)
Inventor
Janet M Hock
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26792729&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20000755(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HRP20000755A2 publication Critical patent/HRP20000755A2/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
HR20000755A 1998-08-19 1999-08-19 Method of increasing bone toughness and stiffness and reducing fractures HRP20000755A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9715198P 1998-08-19 1998-08-19
US9974698P 1998-09-10 1998-09-10
PCT/US1999/018961 WO2000010596A1 (en) 1998-08-19 1999-08-19 Method of increasing bone toughness and stiffness and reducing fractures

Publications (1)

Publication Number Publication Date
HRP20000755A2 true HRP20000755A2 (en) 2001-02-28

Family

ID=26792729

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20000755A HRP20000755A2 (en) 1998-08-19 1999-08-19 Method of increasing bone toughness and stiffness and reducing fractures

Country Status (32)

Country Link
US (2) US6977077B1 (xx)
EP (3) EP2266598B1 (xx)
JP (5) JP2002523375A (xx)
KR (1) KR100454207B1 (xx)
CN (1) CN1205997C (xx)
AR (1) AR033639A1 (xx)
AT (1) ATE231000T1 (xx)
AU (1) AU746277B2 (xx)
BR (1) BR9909445A (xx)
CA (1) CA2325371C (xx)
CO (1) CO5130020A1 (xx)
CY (2) CY1113343T1 (xx)
CZ (1) CZ301017B6 (xx)
DE (2) DE69904918T2 (xx)
DK (4) DK2266598T3 (xx)
DZ (1) DZ2873A1 (xx)
EA (1) EA003362B1 (xx)
ES (4) ES2190244T3 (xx)
HR (1) HRP20000755A2 (xx)
HU (2) HU230697B1 (xx)
ID (1) ID29039A (xx)
IL (2) IL138829A0 (xx)
MY (1) MY129227A (xx)
NO (2) NO323984B1 (xx)
NZ (1) NZ507056A (xx)
PE (1) PE20001089A1 (xx)
PL (1) PL201688B1 (xx)
PT (4) PT2907522T (xx)
TR (1) TR200003455T2 (xx)
TW (1) TW576747B (xx)
UA (1) UA72205C2 (xx)
WO (1) WO2000010596A1 (xx)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770623B1 (en) * 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
US20040033950A1 (en) * 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
AR033639A1 (es) 1998-08-19 2004-01-07 Lilly Co Eli Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
AU7362900A (en) * 1999-09-20 2001-04-24 Eli Lilly And Company Method for monitoring treatment with a parathyroid hormone
US7247609B2 (en) 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
EP1531855A4 (en) * 2002-01-10 2009-07-22 Osteotrophin Llc TREATMENT OF BONE DISEASES WITH SKELETTAL ANABOLIKA
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
KR20060058133A (ko) * 2003-09-19 2006-05-29 화이자 프로덕츠 인코포레이티드 2-알킬리덴-19-노르-비타민 ｄ 유도체 및 부갑상선호르몬의 조합을 포함하는 약학 조성물 및 방법
US20060127320A1 (en) * 2004-05-10 2006-06-15 Nastech Pharmaceutical Company Inc. Method of delivering parathyroid hormone to a human
US20060052305A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. Method of treating osteoporosis using intranasal parathyroid hormone
EP1750756A2 (en) * 2004-05-10 2007-02-14 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
US20060189533A1 (en) * 2004-05-10 2006-08-24 Nastech Pharmaceutical Company Inc. Stable pharmaceutical dosage forms of teriparatide
AU2005244734A1 (en) 2004-05-13 2005-12-01 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents
US7648965B2 (en) 2004-05-14 2010-01-19 Unigene Laboratories Inc. Method for fostering bone formation and preservation
WO2006124062A1 (en) * 2005-05-11 2006-11-23 Unigene Laboratories, Inc. Method for fostering bone formation and preservation
US20060069021A1 (en) * 2004-08-13 2006-03-30 Nastech Pharmaceutical Company Inc. Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
WO2006073711A2 (en) * 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
US8575101B2 (en) 2005-01-06 2013-11-05 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
JP2009515535A (ja) * 2005-11-10 2009-04-16 ボード オブ コントロール オブ ミシガン テクノロジカル ユニヴァーシティー クロクマの副甲状腺ホルモン及びクロクマの副甲状腺ホルモンを使用する方法
US20080051332A1 (en) * 2005-11-18 2008-02-28 Nastech Pharmaceutical Company Inc. Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
US20080119408A1 (en) * 2006-07-07 2008-05-22 Nastech Pharmaceutical Company Inc. Pth formulations for intranasal delivery
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
MX2009011005A (es) 2007-04-13 2009-11-02 Kuros Biosurgery Ag Sellador polimerico para tejido.
US20110137243A1 (en) * 2007-09-06 2011-06-09 Abbott Cardiovascular Systems Inc. Coating On A Balloon Device
WO2009072119A2 (en) * 2007-12-04 2009-06-11 Ben-Gurion University Of The Negev Research And Development Authority Amphiphilic peptide matrices for treatment of osteoporosis
EP2227263A2 (en) 2007-12-28 2010-09-15 Kuros Biosurgery AG Pdgf fusion proteins incorporated into fibrin foams
US20120252729A1 (en) 2009-09-09 2012-10-04 Asahi Kasei Pharma Corporation Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week in a unit dose of 100 to 200 units
WO2011071480A1 (en) 2009-12-07 2011-06-16 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US9295663B2 (en) 2010-07-14 2016-03-29 Abbott Cardiovascular Systems Inc. Drug coated balloon with in-situ formed drug containing microspheres
WO2012111852A1 (ja) * 2011-02-17 2012-08-23 帝人ファーマ株式会社 椎体骨折治療剤及びその評価方法
EP2686027B1 (en) 2011-03-16 2021-05-05 Kuros Biosurgery AG Pharmaceutical formulation for use in spinal fusion
KR20140001255A (ko) 2011-06-07 2014-01-06 아사히 가세이 파마 가부시키가이샤 고순도 ｐｔｈ 함유 동결 건조 제제 및 그의 제조 방법
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
EP3411066A1 (en) 2016-02-01 2018-12-12 Eli Lilly and Company Parathyroid hormone anti-rankl antibody fusion compounds
US20190381341A1 (en) * 2017-02-01 2019-12-19 The Johns Hopkins University Parathyroid hormone and regeneration of degenerative discs disease
CN116898955A (zh) * 2017-09-22 2023-10-20 旭化成制药株式会社 稳定性优异的含有特立帕肽的液态药物组合物
EP3875105B1 (en) 2018-10-29 2024-11-27 Asahi Kasei Pharma Corporation An improved teriparatide dosage regimen for use in preventing or treating osteoporosis characterized by administering teriparatide or salt thereof twice a week
US12344649B2 (en) 2019-08-09 2025-07-01 Flagship Pioneering Innovations Vi, Llc Modulators of parathyroid hormone receptor (PTHR1)
GB2590692A (en) * 2019-12-24 2021-07-07 Corthotec Ltd Composition for improved bone fracture healing

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
DE3935738A1 (de) 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
US5208041A (en) 1991-05-23 1993-05-04 Allelix Biopharmaceuticals Inc. Essentially pure human parathyroid hormone
CA2126299C (en) 1994-06-20 2000-12-12 Gordon E. Willick Parathyroid hormone analogues for the treatment of osteoporosis
JPH0873376A (ja) * 1994-09-07 1996-03-19 Asahi Chem Ind Co Ltd 骨粗鬆症治療薬
US5747456A (en) * 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
WO1996019246A1 (en) * 1994-12-19 1996-06-27 Beth Israel Hospital Association Continuous low-dose administration of parathyroid hormone or its agonist
PL321094A1 (en) * 1994-12-22 1997-11-24 Astra Ab Parathyroid hormone (pth) containing preparation administered by inhalation
JPH08310965A (ja) 1995-05-16 1996-11-26 Chugai Pharmaceut Co Ltd 骨癒合促進剤
PL195703B1 (pl) * 1997-09-09 2007-10-31 Hoffmann La Roche Zastosowanie polipeptydowego analogu peptydu pokrewnego hormonowi przytarczyc
ZA9811127B (en) 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
US20040033950A1 (en) 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
AR033639A1 (es) * 1998-08-19 2004-01-07 Lilly Co Eli Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
US6907597B1 (en) 2000-10-13 2005-06-14 Ati International Srl Method and apparatus for constructing an executable program in memory
US6967759B2 (en) 2001-12-31 2005-11-22 Texas Instruments Incorporated Pulse width modulation sequence generation
JP5796714B2 (ja) 2012-01-13 2015-10-21 株式会社リコー 定着装置及び画像形成装置
EP2949301B1 (en) 2014-05-27 2018-04-18 The Procter and Gamble Company Absorbent core with curved and straight absorbent material areas

Also Published As

Publication number Publication date
CN1308545A (zh) 2001-08-15
EP2266598B1 (en) 2017-02-22
HK1102496A1 (en) 2007-11-23
DK2907522T1 (da) 2015-10-19
ES2621653T3 (es) 2017-07-04
ID29039A (id) 2001-07-26
US6977077B1 (en) 2005-12-20
ES2190244T3 (es) 2003-07-16
ES2549551T1 (es) 2015-10-29
EP2907522B1 (en) 2017-08-02
DK2907522T3 (en) 2017-10-23
DE69904918D1 (de) 2003-02-20
JP2017190332A (ja) 2017-10-19
CA2325371C (en) 2004-08-17
PT2907522T (pt) 2017-10-23
CZ20004134A3 (cs) 2001-08-15
HU230697B1 (hu) 2017-09-28
NZ507056A (en) 2003-10-31
JP2014139220A (ja) 2014-07-31
JP2015028065A (ja) 2015-02-12
CY1113343T1 (el) 2016-06-22
NO20005947D0 (no) 2000-11-24
WO2000010596A1 (en) 2000-03-02
IL138829A (en) 2011-01-31
NO20005947L (no) 2000-11-24
NO20072983L (no) 2000-11-24
IL138829A0 (en) 2001-10-31
HU1200430D0 (hu) 2001-11-28
PT1059933E (pt) 2003-06-30
AU746277B2 (en) 2002-04-18
AR033639A1 (es) 2004-01-07
AU5575099A (en) 2000-03-14
EA003362B1 (ru) 2003-04-24
DK2266598T3 (en) 2017-05-15
NO323984B1 (no) 2007-07-30
TW576747B (en) 2004-02-21
JP2011021035A (ja) 2011-02-03
CO5130020A1 (es) 2002-02-27
MY129227A (en) 2007-03-30
EP2907522A1 (en) 2015-08-19
ES2393200T3 (es) 2012-12-19
PE20001089A1 (es) 2000-11-04
BR9909445A (pt) 2000-12-12
US7163684B2 (en) 2007-01-16
PL201688B1 (pl) 2009-04-30
HUP0101594A2 (hu) 2001-11-28
TR200003455T2 (tr) 2001-06-21
EP1059933B1 (en) 2003-01-15
DK1059933T3 (da) 2003-04-07
US20050197294A1 (en) 2005-09-08
DE69904918T2 (de) 2003-11-13
PT2266598T (pt) 2017-05-02
ES2549551T3 (es) 2017-11-27
CZ301017B6 (cs) 2009-10-14
CN1205997C (zh) 2005-06-15
DZ2873A1 (fr) 2003-12-15
HUP0101594A3 (en) 2002-01-28
CY1119552T1 (el) 2018-03-07
KR100454207B1 (ko) 2004-10-26
ATE231000T1 (de) 2003-02-15
CA2325371A1 (en) 2000-03-02
EA200001015A1 (ru) 2001-02-26
JP2002523375A (ja) 2002-07-30
HK1030545A1 (en) 2001-05-11
HK1212602A1 (en) 2016-06-17
DK1769804T3 (da) 2012-10-15
PL343595A1 (en) 2001-08-27
UA72205C2 (uk) 2005-02-15
EP1059933A1 (en) 2000-12-20
DE15152726T1 (de) 2015-12-10
KR20010072763A (ko) 2001-07-31
JP6177718B2 (ja) 2017-08-09
EP2266598A1 (en) 2010-12-29
PT1769804E (pt) 2012-11-13

Similar Documents

Publication Publication Date Title
US7163684B2 (en) Method of increasing bone toughness and stiffness and reducing fractures
US7351414B2 (en) Method of reducing the risk of bone fracture
EP1136076A1 (en) Method of increasing bone toughness and stiffness and reducing fractures
EP1769804A2 (en) Method of increasing bone toughness and stiffness and reducing fractures
HK1037333A (en) Method of increasing bone toughness and stiffness and reducing fractures
HK1212602B (en) Method of increasing bone toughness and stiffness and reducing fractures
MXPA00009982A (en) Method of increasing bone toughness and stiffness and reducing fractures
HK1030545B (en) Use of parathyroide hormone consisting of aminoacid sequence 1-34 of human parathyroid hormone for reducing the risk of both vertebral and non vertebral bone fracture
HK1102496B (en) Hpth(1-34) for use in preventing or reducing the incidence or severity of vertebral and / or non vertebral fracture in a male human

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODBI Application refused